Posted in | Nanoanalysis

Malvern's Zetasizer Nano Helps Secure 5th Queens Award

Published on September 5, 2010 at 8:39 PM

Sir Michael Brinton, the Lord Lieutenant* of Worcestershire, today formally presented the 2010 Queen's Award for Enterprise in Innovation to materials characterization company Malvern Instruments in a ceremony held at its UK headquarters and attended by employees from all parts of the organisation. This is Malvern's fifth Queen's Award and this year recognises the company's continuous development of its market-leading Zetasizer Nano particle characterization systems.

Sir Michael made the presentation following a tour of Malvern's facility during which he talked with people across the company, from manufacturing on the shop floor right through to the boardroom.

Accepting the 2010 Queen's Award, Malvern's Managing Director Paul Walker told the audience how proud he is of the achievements of the whole company. "Malvern Instruments was established some forty years ago to commercialise a technological innovation, and while we have come a long way since then in building a global and more diversified business, we have certainly not forgotten our roots," he said. "I believe that winning this award, specifically for innovation, pays great tribute to the vision, knowledge, expertise and sheer hard work of individuals and teams within our company. However, it's not only a tribute to those with the technology know-how, but also to everyone in the wider organisation whose individual contribution is vital to Malvern's success."

Malvern is a global company that delivers materials characterization systems, support and expertise. The Zetasizer Nano exemplifies how Malvern scientists and engineers understand the needs of their customers and make highly sophisticated technology accessible to users from different backgrounds and having varying levels of expertise. Automation and software-driven measurement make the Zetasizer Nano a system that is universally easy to use, and one that is essential in many projects from cutting-edge drug discovery to routine quality control.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit